Business
The limited supply of this common reagent is set to drive drug prices higher, but there are ways for companies to lessen the impact.
FEATURED STORIES
The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two approved assets enough to maintain investor interest?
A rapturous response to data published last year for Pelage’s hair loss candidate overwhelmed the biotech. Now, the company is ready to show the world the science behind the breakthrough.
Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Last week was a relatively quiet week for clinical trial news, particularly around COVID-19. Here’s a look.
The Biotechnology Innovation Organization provides a glimpse of economic development in the biosciences ecosystem at the state and regional levels.
The data is coming in right away for Alnylam in one of its primary indications, transthyretin-mediated (ATTR) amyloidosis.
Merck announced that Frank Clyburn, executive vice president and president of human health, will be leaving the company on February 1, 2022.
Biopharma and life sciences companies made numerous appointments this week to boards and executive teams. These Movers & Shakers will position the companies for future growth.
Laurence F. Doud III, the former chief executive officer of Rochester Drug Co-Operative, Inc. (RDC), one of the 10 largest pharmaceutical distributors in the United States, ignored what U.S. prosecutors have called “serious red flags” surrounding the sale of opioid drugs.
Psychedelic-focused drug company Eleusis is merging with Silver Spike Acquisition Corp. II, a special purposes acquisition company, and heading to the Nasdaq with a combined enterprise value of $446 million.
As part of a company-wide workforce reduction, it will cut its employee headcount by at least 25% by the end of the year, and 50% of its senior management team are leaving the company.
World tennis superstar Novak Djokovic reportedly has an 80% stake in QuantBioRes that’s currently working on finding a treatment, not a vaccine, for COVID-19.
The funds will be used to advance the firm’s precision oncology research efforts and pipeline, particularly those involving the creation of alteration-specific therapies.